Enoxaparin vs Fondaparinux Dalam Penurunan CK-MB

yedy purwandi sukmawan (Sekolah Tinggi Ilmu Kesehatan Bakti Tunas Husada)
Keni Idacahyati (Sekolah Tinggi Ilmu Kesehatan Bakti Tunas Husada)
Rezky Fahrizal Firdaus (Sekolah Tinggi Ilmu Kesehatan Bakti Tunas Husada)

Jurnal Farmasi Indonesia
Vol 17 No 2 (2020): Jurnal Farmasi Indonesia

Ischemic Heart Disease (Non ST Elevated Myocardial Infarction-NSTEMI) is the leading cause of death in Indonesia after Stroke. Enoxaparin and Fondaparinux are the drugs of choice for this condition. However, there is a little study about these drugs in Indonesian people. Therefore, the objective of the study is to determine the effectivity of enoxaparin and fondaparinux in CK-MB reduction in Indonesian people. The methods of the study is retrospective observational study. A total of 43 patients were met inclusion criteria (32 in the enoxaparin group and 11 in the fondaparinux group). The outcome of the study was CK-MB reduction and the time of dyspnea was disappeared. The results of the study showed no statistic difference between enoxaparin and fondaparinux in reducing CK-MB blood plasma level (-29.00 vs -33.09; p 0.715), and also the time of dyspnea was disappeared (3.44 vs 3.09 days; p 0.347). Therefore, the choice of these agents are based on clinical condition, adverse effects and pharmacoeconomic aspects.